ALK 阳性非小细胞肺癌的治疗：最新进展。
Treatment of ALK-positive nonsmall cell lung cancer: recent advances.
机构信息
Department of Medical Oncology, Peter MacCallum Cancer Centre.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
出版信息
Curr Opin Oncol. 2018 Mar;30(2):84-91. doi: 10.1097/CCO.0000000000000431.
PURPOSE OF REVIEW
The review will highlight recent advances in development of ALK-TKIs and management of patients with ALK-positive nonsmall cell lung cancer.
RECENT FINDINGS
There has been rapid progress in the use of targeted therapies for ALK-positive NSCLC. Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA. A range of newer generation ALK inhibitors with improved potency against ALK and against mutations that confer resistance to crizotinib are in clinical development.
SUMMARY
Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.
目的综述
本文将重点介绍 ALK-TKIs 的最新进展以及 ALK 阳性非小细胞肺癌的治疗管理。
最近发现
针对 ALK 阳性 NSCLC 的靶向治疗已取得飞速发展。自 2011 年克唑替尼被发现、研发并获得 FDA 批准以来，已有三种第二代 ALK-TKIs（色瑞替尼、阿来替尼和布加替尼）获得批准。目前，有一系列新型、作用更强的 ALK 抑制剂正在研发中，可针对 ALK 并克服对克唑替尼耐药的突变。
总结
我们的综述将讨论色瑞替尼和阿来替尼的最新 III 期数据，以及其他 ALK 抑制剂的临床试验。我们还将讨论 ALK 阳性 NSCLC 管理中的两个重要问题，即脑转移的预防和治疗以及紧急 ALK-TKI 耐药机制的管理。
Zotero 插件